Identification of Anti-Influenza A Compounds Inhibiting the Viral Non-Structural Protein 1 (NS1) Using a Type I...

Area of Science:

• Virology
• Drug Discovery
• Immunology

Background:

• Influenza viruses pose a significant threat, necessitating new antiviral treatments due to emerging drug resistance.
• Current antivirals target M2, NA, or endonuclease, but resistance limits their long-term efficacy.
• The influenza A non-structural protein 1 (NS1) is a key viral factor inhibiting host immune responses.

Purpose of the Study:

• To identify novel antiviral compounds targeting influenza A virus.
• To investigate compounds that antagonize the function of the NS1 protein.
• To explore new therapeutic strategies against influenza A virus infections.

Main Methods:

• A cell-based screening assay was employed using a small molecule library.
• Screening focused on identifying compounds that antagonize influenza A non-structural protein 1 (NS1).
• Antiviral activity was assessed by measuring viral replication and host interferon-beta (IFN-β) expression.

Main Results:

• Two compounds, 157 and 164, demonstrated anti-NS1 activity.
• These compounds reduced the replication of A/PR/8/34(H1N1) influenza A virus.
• Compounds 157 and 164 restored IFN-β expression in infected human lung epithelial A549 cells.
• 3D pharmacophore modeling provided insights into structural features of active compounds.

Conclusions:

• Compounds 157 and 164 are potential anti-influenza agents targeting the NS1 protein.
• Inhibiting NS1 offers a novel mechanism for combating influenza A virus.
• The screening approach can be applied to discover inhibitors for other viral targets.